Gene Signal: In the Media

Gene Signal’s CEO Eric Viaud speaks to the editor of Biotech Intelligence on the potential of GS-101, Gene Signal’s first drug candidate for Corneal Graft Rejection.

www.biotech-intelligence.com/interview.php

Gene Signal’s GS-101 antisense oligonucleotide is ranked first on the list of ‘The Five Most Promising Drugs Entering Phase III Trials’ published in Thomson Reuter’s ’The Ones to Watch’ report.

The Ones to Watch is a Pharma Matters Quarterly Report which issues expert reviews on the most promising drugs changing clinical phase, receiving approval and launched, based on the strategic data and insight of Thomson Pharma®.
View the document (PDF file)

The potential for Gene Signal’s pipeline of antisense oligonucleotides across a variety of ophthalmic indications including Diabetic Retinopathy and Age Related Macular Degeneration is reported in the March 2^nd issue of the IMS’s ‘R&D FOCUS Drug News’.

The IMS R&D Focus Drug News publishes up-to-date intelligence on drugs in R&D development worldwide. It evaluates the progress of R&D pipelines from discovery phase
to marketed Phase.
View the document (PDF file)

Gene Signal’s CEO Eric Viaud speaks to the editor of Biotech Intelligence on the potential of GS-101, Gene Signal’s first drug candidate for Corneal Graft Rejection.

Gene Signal’s GS-101 antisense oligonucleotide is ranked first on the list of ‘The Five Most Promising Drugs Entering Phase III Trials’ published in Thomson Reuter’s ’The Ones to Watch’ report.

The potential for Gene Signal’s pipeline of antisense oligonucleotides across a variety of ophthalmic indications including Diabetic Retinopathy and Age Related Macular Degeneration is reported in the March 2nd issue of the IMS’s ‘R&D FOCUS Drug News’.

The potential for Gene Signal’s pipeline of antisense oligonucleotides across a variety of ophthalmic indications including Diabetic Retinopathy and Age Related Macular Degeneration is reported in the March 2^nd issue of the IMS’s ‘R&D FOCUS Drug News’.